How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.



Source link